<DOC>
	<DOCNO>NCT00933205</DOCNO>
	<brief_summary>The purpose Open Label Safety Study provide access evaluate safety tolerability TPV/r treatment-experienced patient advance HIV-1 infection fail least two PI-containing regimen , limited treatment option .</brief_summary>
	<brief_title>An Open Label Safety Study Tipranavir Co-administered With Low-dose Ritonavir Patients With Advanced HIV-1 Infection Limited Treatment Options .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>1 . Triple antiretroviral class experience patient least 2 previous PIbased regimen fail intolerant currently approve HIV1 treatment . 2 . Age equal 18 year 3 . Patient willing use effective barrier method contraception duration study participation three month thereafter 4 . Patient voluntarily provide write informed consent participate , compliance local law . 1 . Hypersensitivity active ingredient excipients tipranavir ritonavir 2 . Required use restricted medication . 3 . Female patient childbearing potential positive pregnancy test baseline breast feeding . 4 . Any medical condition opinion investigator would interfere patient ' ability participate adhere requirement protocol . 5 . Use investigational drug , within 30 day prior TPV boost ritonavir initiation duration study participation 6 . Hepatic impairment evidence follow baseline laboratory finding : AST ALT 5X ULN total bilirubin 3.5X ULN AST ALT 2.5X ULN total bilirubin 2X ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>